Swedbank AB Sells 148,672 Shares of Globus Medical, Inc. $GMED

Swedbank AB trimmed its holdings in shares of Globus Medical, Inc. (NYSE:GMED) by 21.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 530,403 shares of the medical device company’s stock after selling 148,672 shares during the quarter. Swedbank AB owned approximately 0.40% of Globus Medical worth $46,309,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the business. Fideuram Intesa Sanpaolo Private Banking S.P.A. bought a new stake in Globus Medical during the fourth quarter valued at approximately $1,330,000. Legato Capital Management LLC grew its position in Globus Medical by 2.6% during the fourth quarter. Legato Capital Management LLC now owns 23,228 shares of the medical device company’s stock valued at $2,028,000 after buying an additional 595 shares during the period. Meiji Yasuda Asset Management Co Ltd. bought a new stake in Globus Medical during the fourth quarter valued at approximately $223,000. Global Retirement Partners LLC grew its position in Globus Medical by 692.8% during the fourth quarter. Global Retirement Partners LLC now owns 5,058 shares of the medical device company’s stock valued at $442,000 after buying an additional 4,420 shares during the period. Finally, PNC Financial Services Group Inc. grew its position in Globus Medical by 31.1% during the fourth quarter. PNC Financial Services Group Inc. now owns 11,679 shares of the medical device company’s stock valued at $1,020,000 after buying an additional 2,771 shares during the period. 95.16% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Globus Medical news, EVP Kelly Huller sold 20,000 shares of Globus Medical stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $94.50, for a total transaction of $1,890,000.00. The sale was disclosed in a filing with the SEC, which is accessible through this link. 18.38% of the stock is owned by corporate insiders.

Globus Medical Price Performance

Shares of NYSE:GMED opened at $84.84 on Monday. Globus Medical, Inc. has a 1-year low of $51.79 and a 1-year high of $101.40. The company has a market capitalization of $11.52 billion, a P/E ratio of 19.73, a P/E/G ratio of 1.75 and a beta of 1.00. The firm’s 50 day simple moving average is $87.26 and its two-hundred day simple moving average is $87.99.

Globus Medical (NYSE:GMED) last issued its quarterly earnings results on Thursday, May 7th. The medical device company reported $1.12 earnings per share for the quarter, beating the consensus estimate of $0.92 by $0.20. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. The business had revenue of $759.85 million for the quarter, compared to the consensus estimate of $740.35 million. During the same quarter in the previous year, the firm earned $0.68 earnings per share. The company’s revenue for the quarter was up 27.0% on a year-over-year basis. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. On average, sell-side analysts anticipate that Globus Medical, Inc. will post 4.74 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on GMED. Truist Financial set a $115.00 target price on shares of Globus Medical in a research report on Wednesday, February 25th. Wells Fargo & Company cut their target price on shares of Globus Medical from $104.00 to $103.00 and set an “overweight” rating for the company in a research report on Friday, May 8th. TD Cowen upgraded shares of Globus Medical to a “strong-buy” rating in a research report on Tuesday, January 27th. Weiss Ratings restated a “hold (c+)” rating on shares of Globus Medical in a research report on Wednesday, April 15th. Finally, Needham & Company LLC boosted their target price on shares of Globus Medical from $114.00 to $117.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Two research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat.com, Globus Medical has a consensus rating of “Moderate Buy” and a consensus price target of $106.36.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.